The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Alkylamides from Echinacea Are a New Class of Cannabinomimetics
Open accessAbstract
Alkylamides (alkamides) from Echinacea modulate tumor necrosis factor alpha mRNA expression in human monocytes/macrophages via the cannabinoid type 2 (CB2) receptor (Gertsch, J., Schoop, R., Kuenzle, U., and Suter, A. (2004) FEBS Lett. 577, 563-569). Here we show that the alkylamides dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (A1) and dodeca-2E,4E-dienoic acid isobutylamide (A2) bind to the CB2 receptor more strongly than the endogenous cannabinoids. The Ki values of A1 and A2 (CB2 approximately 60 nM; CB1 >1500 nM) were determined by displacement of the synthetic high affinity cannabinoid ligand [3H]CP-55,940. Molecular modeling suggests that alkylamides bind in the solvent-accessible cavity in CB2, directed by H-bonding and pi-pi interactions. In a screen with 49 other pharmacologically relevant receptors, it could be shown that A1 and A2 specifically bind to CB2 and CB1. A1 and A2 elevated total intracellular Ca2+ in CB2-positive but not in CB2-negative promyelocytic HL60 cells, an effect that was inhibited by the CB2 antagonist SR144528. At 50 nM, A1, A2, and the endogenous cannabinoid anandamide (CB2 Ki >200 nM) up-regulated constitutive interleukin (IL)-6 expression in human whole blood in a seemingly CB2-dependent manner. A1, A2, anandamide, the CB2 antagonist SR144528 (Ki <10 nM), and also the non-CB2-binding alkylamide undeca-2E-ene,8,10-diynoic acid isobutylamide all significantly inhibited lipopolysaccharide-induced tumor necrosis factor alpha, IL-1beta, and IL-12p70 expression (5-500 nM) in a CB2-independent manner. Alkylamides and anandamide also showed weak differential effects on anti-CD3-versus anti-CD28-stimulated cytokine expression in human whole blood. Overall, alkylamides, anandamide, and SR144528 potently inhibited lipopolysaccharide-induced inflammation in human whole blood and exerted modulatory effects on cytokine expression, but these effects are not exclusively related to CB2 binding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443
Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., LE Fur, G., & Casellas, P. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20780.x · Cited by 1,749
Cachectin and tumour necrosis factor as two sides of the same biological coin
Beutler, B., & Cerami, A. (1986) · Nature · doi:10.1038/320584a0 · Cited by 1,647
Control of pain initiation by endogenous cannabinoids
Calignano, A., Rana, G. L., Giuffrida, A., & Piomelli, D. (1998) · Nature · doi:10.1038/28393 · Cited by 1,056
The two faces of IL-6 on Th1/Th2 differentiation
Diehl, S., & Rincón, M. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00210-9 · Cited by 872
Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-6
Jones, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.6.3463 · Cited by 771
Cannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728
SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor
Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.-M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37266-0 · Cited by 709
Showalter, V. M., Compton, D. R., Martin, B. R., & Abood, M. E. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20744-3 · Cited by 571
The cannabinoid system and immune modulation
Klein, T. W., Newton, C., Larsen, K., Lu, L., Perkins, I., Nong, L., & Friedman, H. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 524
The endocannabinoid system: a general view and latest additions
Petrocellis, L. D., Cascio, M. G., & Marzo, V. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705666 · Cited by 475
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice
Steffens, S., Veillard, N. R., Arnaud, C., Pelli, G., Burger, F., Staub, C., Zimmer, A., Frossard, J.-L., & Mach, F. (2005) · Nature · doi:10.1038/nature03389 · Cited by 472
Sagara, Y., & Inesi, G. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)92726-2 · Cited by 454
Barnes, J., Anderson, L. A., Gibbons, S., & Phillipson, J. D. (2005) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357056127 · Cited by 424
Demuth, D. G., & Molleman, A. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.05.055 · Cited by 420
Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H., & Waku, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.605 · Cited by 371
Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T., & Kaminski, N. E. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1996.8034 · Cited by 358
Carlisle, S. J., Marciano-Cabral, F., Staab, A., Ludwick, C., & Cabral, G. A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00147-3 · Cited by 344
Inhibition of tumor angiogenesis by cannabinoids
Blázquez, C., Casanova, M. L., Planas, A., Gómez del Pulgar, T., Villanueva, C., Fernández‐Aceñero, M. J., Aragonés, J., Huffman, J. W., Jorcano, J. L., & Guzmán, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0795fje · Cited by 292
Cannabinoid receptors and the regulation of immune response
Berdyshev, E. V. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00195-x · Cited by 280
Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases?
Croxford, J. L., & Yamamura, T. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.04.023 · Cited by 255
Kaminski, N. E., Abood, M. E., Kessler, F. K., Martin, B. R., & Schatz, A. R. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09130-8 · Cited by 248
Inhibition of Inflammatory Hyperalgesia by Activation of Peripheral CB2Cannabinoid Receptors
Quartilho, A., Mata, H. P., Ibrahim, M. M., Vanderah, T. W., Porreca, F., Makriyannis, A., & Malan, T. P. (2003) · Anesthesiology · doi:10.1097/00000542-200310000-00031 · Cited by 242
Cannabinoid Receptor as a Novel Target for the Treatment of Prostate Cancer
Sarfaraz, S., Afaq, F., Adhami, V. M., & Mukhtar, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3410 · Cited by 240
An Evaluation of Echinacea angustifolia in Experimental Rhinovirus Infections
Turner, R. B., Bauer, R., Woelkart, K., Hulsey, T. C., & Gangemi, J. D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044441 · Cited by 236
Percival, S. S. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00413-x · Cited by 208
Gertsch, J., Schoop, R., Kuenzle, U., & Suter, A. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.10.064 · Cited by 206
Self-citationMcAllister, S. D., Rizvi, G., Anavi-Goffer, S., Hurst, D. P., Barnett-Norris, J., Lynch, D. L., Reggio, P. H., & Abood, M. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0302647 · Cited by 185
Presence and regulation of the endocannabinoid system in human dendritic cells
Matias, I., Pochard, P., Orlando, P., Salzet, M., Pestel, J., & Di Marzo, V. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.03078.x · Cited by 179
Lunn, C. A., Fine, J. S., Rojas-Triana, A., Jackson, J. V., Fan, X., Kung, T. T., Gonsiorek, W., Schwarz, M. A., Lavey, B. J., Kozlowski, J. A., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.093500 · Cited by 145
Echinaforce® and other Echinacea fresh plant preparations in the treatment of the common cold
Brinkeborn, R. M., Shah, D. V., & Degenring, F. H. (1999) · Phytomedicine · doi:10.1016/s0944-7113(99)80027-0 · Cited by 143
Agonist-Directed Trafficking of Response by Endocannabinoids Acting at CB2 Receptors
Shoemaker, J. L., Ruckle, M. B., Mayeux, P. R., & Prather, P. L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089474 · Cited by 133
Zoratti, C., Kipmen‐Korgun, D., Osibow, K., Malli, R., & Graier, W. F. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705529 · Cited by 131
Song, Z. H., Slowey, C.-A., Hurst, D. P., & Reggio, P. H. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12547-3 · Cited by 125
Anandamide Inhibits Nuclear Factor-κB Activation through a Cannabinoid Receptor-Independent Pathway
Sancho, R., Calzado, M. A., Di Marzo, V., Appendino, G., & Muñoz, E. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.429 · Cited by 120
Goel, V., Lovlin, R., Barton, R., Lyon, M. R., Bauer, R., Lee, T. D. G., & Basu, T. K. (2004) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2003.00542.x · Cited by 113
3D structural model of the G‐protein‐coupled cannabinoid CB2 receptor
Xie, X., Chen, J., & Billings, E. M. (2003) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.10511 · Cited by 106
Self-citationMolina‐Holgado, F., Molina‐Holgado, E., & Guaza, C. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00851-5 · Cited by 106
Shire, D. J., Calandra, B., Delpech, M., Dumont, X., Kaghad, M., Fur, G. L., Caput, D., & Ferrara, P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.12.6941 · Cited by 96
Oka, S., Shin, Y., Ikeda, S., Gokoh, M., Kishimoto, S., Waku, K., Ishima, Y., & Sugiura, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413260200 · Cited by 92
Kishimoto, S. (2004) · The Journal of Biochemistry · doi:10.1093/jb/mvh063 · Cited by 88
Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion
Matthias, A., Addison, R. S., Penman, K. G., et al. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.04.009 · Cited by 84
Evidence for Cannabinoid Receptor-Dependent and -Independent Mechanisms of Action in Leukocytes
Kaplan, B. L. F., Rockwell, C. E., & Kaminski, N. E. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051961 · Cited by 83
Klein, T., Newton, C., Widen, R. H., & Friedman, H. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39360-2 · Cited by 76
Randolph, R. K., Gellenbeck, K. W., Stonebrook, K., et al. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800910 · Cited by 70
Bioavailability and Pharmacokinetics of Alkamides From the Roots of Echinacea angustifolia in Humans
Woelkart, K., Koidl, C., Grisold, A. J., et al. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004273493 · Cited by 70
Gouldson, P. R., Calandra, B., Legoux, P., et al. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00439-8 · Cited by 58
Jbilo, O., Derocq, J., Ségui, M., Fur, G. L., & Casellas, P. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00380-4 · Cited by 57
Lograno, M. D., & Romano, M. R. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.04.039 · Cited by 49
Skapenko, A., Lipsky, P. E., Kraetsch, H.-G., Kalden, J. R., & Schulze-Koops, H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.7.4283 · Cited by 42
Feng, W., & Song, Z. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00005-4 · Cited by 42
Rao, G. K., Zhang, W., & Kaminski, N. E. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.1203638 · Cited by 38
Cited by
Beta-caryophyllene is a dietary cannabinoid.
Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J.-Z., Xie, X.-Q., Altmann, K.-H., Karsak, M., & Zimmer, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803601105 · Cited by 906
Self-citationSynergy and antagonism in natural product extracts: when 1 + 1 does not equal 2
Caesar, L. K., & Cech, N. B. (2019) · Natural Product Reports · doi:10.1039/c9np00011a · Cited by 881
Cannabis, a complex plant: different compounds and different effects on individuals
Atakan, Z. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312457586 · Cited by 544
Immunomodulators Inspired by Nature: A Review on Curcumin and Echinacea
Catanzaro, M., Corsini, E., Rosini, M., Racchi, M., & Lanni, C. (2018) · Molecules · doi:10.3390/molecules23112778 · Cited by 258
Phytocannabinoids beyond the Cannabis plant – do they exist?
Gertsch, J., Pertwee, R. G., & Di Marzo, V. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00745.x · Cited by 188
Self-citation
Metadata
- Authors
- Raduner, S., Majewska, A., Chen, J.-Z., Xie, X.-Q., Hamon, J., Faller, B., Altmann, K.-H., & Gertsch, J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 281
- Issue
- 20
- Pages
- 14192-14206
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2016128034
- Cited by
- 258
- References
- 56
- FWCI
- 10.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.